<DOC>
	<DOC>NCT01220934</DOC>
	<brief_summary>This observational, multicenter study will assess the efficacy and safety of Herceptin (trastuzumab) in routine clinical practice in patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-esophageal junction. Data from patients will be collected for approximately 12 months.</brief_summary>
	<brief_title>An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Histologically confirmed advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ) with locally advanced and/or metastatic disease HER2positive tumor Patients who are eligible for treatment with Herceptin according to the judgment of the physician Unwilling or unable to sign informed consent form Any contraindications, interactions and incompatibilities to Herceptin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>